Trial abstracts in the registry — page 2
700 documents of type trial abstract.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over 72 weeks. The Institute holds no reported primary result for this…
27 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low26 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over 72 weeks. Primary result: The Institute holds a headline result indicating a…
Moderate21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Feb 2026 -
Single-arm open-label, phase 3 study of Orforglipron in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute…
Very low15 Feb 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low10 Feb 2026 -
Single-arm open-label, phase 3 study of Retatrutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low09 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over 42 weeks. The Institute holds no reported primary result for this record and…
01 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low29 Jan 2026 -
Randomised crossover, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low26 Jan 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low24 Jan 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low18 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low17 Jan 2026 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity randomising 3,417 participants over 68 weeks. Primary…
Moderate12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in sleep apnoea over 52 weeks. The Institute holds no reported primary result for this record…
11 Jan 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low05 Jan 2026 -
Single-arm open-label, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over open-label extension of the parent trial. The…
Very low24 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over 68 weeks. Primary result: Improvement relative to…
Low19 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low09 Dec 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes randomising 792 participants over 52 weeks…
Moderate08 Dec 2025 -
Phase 1 ascending dose, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Dec 2025 -
Event-driven cardiovascular outcome trial, phase 3 study of Tirzepatide in cardiovascular and type 2 diabetes randomising 13,299 participants over median 4.5 years…
Moderate28 Nov 2025 -
Single-arm open-label, phase 3 study of Mazdutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low18 Nov 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity randomising 664 participants over 48 weeks. Primary result: Mean change −13.2 % at…
Low01 Nov 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent…
Very low15 Oct 2025 -
Observational, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Oct 2025 -
Single-arm open-label, phase 3 study of Ecnoglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low26 Sep 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Sep 2025
page 2 of 18